CHEMM ChemoMetec

Major shareholder announcement – AIM International Mutual Funds

Major shareholder announcement – AIM International Mutual Funds

ANNOUNCEMENT NO. 287

9 December 2024

Major shareholder announcement



Major shareholder announcement – AIM International Mutual Funds         

Pursuant to Section 30 of the Capital Markets Act, it is hereby announced that Invesco Ltd. has informed ChemoMetec A/S that AIM International Mutual Funds (Invesco International Mutual Funds) on 4 December 2024, decreased its holding of voting rights attached to shares and voting rights in ChemoMetec A/S to below 5%, and that the holding thus is below the 5 per cent limit in section 38 of the Capital Markets Act.



Additional information

Martin Helbo Behrens, CEO

Tel.: (+45) 48 13 10 20

Kim Nicolajsen, CFO

Tel.: (+45) 48 13 10 20

About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements.

ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies.

ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For more information, go to



EN
09/12/2024

Underlying

CHEMMChemoMetec

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ChemoMetec

Free Trial
CHEMM CHEMOMETEC

ChemoMetec A S: 1 director

A director at ChemoMetec A S bought 865 shares at 574.030DKK and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

15h / 42m 15h / 42m 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

Notification of managers' transactions

Notification of managers' transactions ANNOUNCEMENT NO. 288 10 February 2025 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them. See the transactions of the Chair of ChemoMetec’s Board of Directors Niels Thestrup in the attached PDF document. For further information, please contact: Kim Nicolajsen, CFOTelephone (+45) 48 13 1...

February 10, 2025 1 EN
Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
CHEMM CHEMOMETEC

ChemoMetec (Buy, TP: DKK675.00) - Growth that counts

ChemoMetec again reported solid results, well above expectations, despite its raised guidance in January, which looks increasingly conservative. It was notably a broad-based beat, with all product segments exceeding expectations. We are especially encouraged by the continued solid rebound in Instrument sales, helped by recent product launches. Margins were also strong (especially versus consensus), suggesting robust operating leverage. We reiterate our BUY and have increased our target price to ...

02/06/25 February 6, 2025 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

1. halvår 2024/25 - Godt første halvår med vækst i både omsætning og d...

1. halvår 2024/25 - Godt første halvår med vækst i både omsætning og driftsresultat MEDDELELSE NR. 2875. februar 2025 Godt første halvår med vækst i både omsætning og driftsresultat  Martin Helbo Behrens, CEO: Fremgangen er fortsat i 2. kvartal 2024/25, og i 1. halvår steg omsætningen til DKK 251,5 mio., svarende til en vækst på 26% sammenlignet med samme periode sidste år. Væksten var blandt andet drevet af enkelte større ordrer på de nye XcytoMatic-instrumenter i kølvandet på de igangsatte kundevalideringer i foråret 2024. I 1. halvår har vi samtidig fastholdt vores kommercielle fo...

February 5, 2025 1 EN
 PRESS RELEASE
Free
CHEMM CHEMOMETEC

Interim report 2024/25 - Solid H1 performance driven by growth in both...

Interim report 2024/25 - Solid H1 performance driven by growth in both revenue and earnings ANNOUNCEMENT NO. 2875 February 2025 Solid H1 performance driven by growth in both revenue and earnings Martin Helbo Behrens, CEO: The growth continued in the second quarter of 2024/25, and revenue for the first half of the year was up to DKK 251.5 million, a year-on-year increase of 26%. Growth was supported by a few large orders for the new XcytoMatic instruments in the wake of the customer validations initiated in the spring of 2024. Concurrently, we maintained our commercial focus in the f...

February 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch